Clinical Trials

660 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03164616 2026-03-13

POSEIDON

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 1 FDA

Urinary Bladder Neoplasms

NCT05687266 2026-03-13

AVANZAR

1,350 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

669 enrolled 54 charts

Non Small Cell Lung Carcinoma NSCLC

NCT03847428 2026-03-06

EMERALD-2

908 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05170204 2026-03-06

HORIZON 1

71 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02453282 2026-03-02

MYSTIC

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03706690 2026-03-02

PACIFIC-5

407 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT03875235 2026-02-27

TOPAZ-1

810 enrolled 24 charts 1 FDA

Biliary Tract Neoplasms

NCT05771480 2026-02-23

TOURMALINE

142 enrolled

Biliary Tract Neoplasms

NCT03682068 2026-02-03

NILE

1,246 enrolled

Urinary Bladder Neoplasms

NCT04550260 2026-01-29

KUNLUN

640 enrolled

Esophageal Squamous Cell Carcinoma

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT05221840 2026-01-27

PACIFIC-9

1,051 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06591520 2026-01-21

AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

682 enrolled

Biliary Tract Neoplasms

NCT03778957 2026-01-16

EMERALD-1

724 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06746116 2026-01-16

DUoENDE

45 enrolled

Gynecologic

Endometrial Neoplasms

NCT03298451 2026-01-14

HIMALAYA

1,324 enrolled 31 charts 1 FDA

Carcinoma, Hepatocellular

NCT04269200 2025-12-23

DUO-E

805 enrolled 18 charts 1 FDA

Gynecologic

Endometrial Neoplasms

NCT04960709 2025-12-19

VOLGA

712 enrolled

Urinary Bladder Neoplasms

NCT06112379 2025-12-17

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

1,902 enrolled

Breast

Breast Neoplasms

NCT06211036 2025-12-17

DeLLphi-305

563 enrolled

Small Cell Lung Carcinoma

NCT03784014 2025-12-11

MULTISARC

603 enrolled

Sarcoma

Neoplasm Metastasis, Sarcoma

NCT03528694 2025-11-25

POTOMAC

1,018 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT03703297 2025-11-21

ADRIATIC

730 enrolled 19 charts 1 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT05450692 2025-11-19

LATIFY

594 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03519971 2025-10-28

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

328 enrolled 23 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03043872 2025-10-21

CASPIAN

987 enrolled 42 charts 2 FDA

Small Cell Lung Carcinoma

NCT02273375 2025-08-12

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

1,415 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05298423 2025-08-01

KEYVIBE-006

611 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03800134 2025-06-11

AEGEAN

825 enrolled 1 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05043090 2025-05-08

SAMETA

148 enrolled

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT03737643 2025-01-29

DUO-O

1,407 enrolled 2 FDA

Gynecologic

Ovarian Neoplasms

NCT04597671 2025-01-29

NVALT28

170 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04637594 2025-01-15

IMAGINE

3 enrolled

Carcinoma, Transitional Cell

NCT05301842 2025-01-15

EMERALD-3

760 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01993810 2024-12-18

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

330 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04116047 2024-07-29

CompARE